ArticleBioengineering (Basel, Switzerland)2024
Pretreatment Sarcopenia and MRI-Based Radiomics to Predict the Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Associations of body composition with neoadjuvant chemotherapy response, toxicity, and prognosis in breast cancer: a scoping review.Cancer chemotherapy and pharmacology · 2026Article
- S100A9 as a shared biomarker and mediator of metabolic dysfunction in peripheral artery disease and sarcopenia.Frontiers in genetics · 2026Article
- The relationship between sarcopenia and breast cancer: mechanistic pathways and clinical relevance.Frontiers in cell and developmental biology · 2026Review
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
- Artificial intelligence standardizes CT-based body composition analysis in breast cacer to address methodological heterogeneity.Frontiers in oncology · 2026Review
- Muscle MR Radiomics for Evaluation of Idiopathic Inflammatory MyopathiesCurrent medical imaging · 2026Article
- Mitochondria-targeted strategies in cancer radiotherapy: from ROS regulation to immunogenic cell death.Frontiers in cell and developmental biology · 2026Review
- Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Effective imaging examination evaluation method for surgical pathological complete responds of head and neck squamous cell carcinoma after neoadjuvant immunochemotherapy.Frontiers in oncology · 2025Article
- Molecular markers for the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The association between sarcopenia and the effectiveness of neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) remains uncertain. This study aims to examine the potential of sarcopenia as a predictive factor for the response to NAC in TNBC, and to assess whether its combination with MRI radiomic signatures can improve the predictive accuracy. We collected clinical and pathological information, as well as pretreatment breast MRI and abdominal CT images, of 121 patients with TNBC who underwent NAC at our hospital between January 2012 and September 2021. The presence of pretreatment sarcopenia was assessed using the L3 skeletal muscle index. Clinical models were constructed based on independent risk factors identified by univariate regression analysis. Radiomics data were extracted on breast MRI images and the radiomics prediction models were constructed. We integrated independent risk factors and radiomic features to build the combined models. The results of this study demonstrated that sarcopenia is an independent predictive factor for NAC efficacy in TNBC. The combination of sarcopenia and MRI radiomic signatures can further improve predictive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.